Cytek Q3 revenue $34.4M (+37% YoY); net income $1.6M down from $6.5M

Cytek Biosciences, Inc.

2022-Q3 EPS reported $0.00 revenue$89,056,000

Total revenue $34.4M, up 37% YoY; gross margin 62% (non-GAAP 64%).
Net income $1.6M, down from $6.5M YoY; non-GAAP net income $4.1M vs $6.7M.
Operating expenses $18.3M, up 106% YoY due to public company costs and R&D investment.
Cash $377M; installed base expanded to 970 instruments with 115 placements in Q3.
Announced acquisition of Tonbo Biosciences' cell analysis business to enhance reagent portfolio.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.